EUVIMEDEUVIMED entdecken
Übersichtsarbeit

HBV antigen as a tumour antigen in adoptive TCR-T cell therapy for HBV-related HCC: rationale and clinical effectiveness

Shan He, Anthony T Tan, Antonio Bertoletti

Seminars in Immunology · 2025

DOI: 10.1016/j.smim.2025.102004 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Seminars in Immunology, 2025. Verfasst von Shan He und 2 weiteren Autor:innen. Beteiligte Einrichtung: Programme Emerging Infectious Diseases, Duke-NUS Medical School, Singapore. Hauptthemen laut MEDLINE: Liver Neoplasms, Carcinoma, Hepatocellular, Immunotherapy, Adoptive, Hepatitis B virus. Die Arbeit nennt 62 Literaturangaben. Gefördert von: Government of Singapore Ministry of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hepatocellular carcinoma developing in patients with HBV chronic infection are marked by expression of whole or partial HBV antigens through a highly tissue-specific process, determined by the hepatotropism of HBV. HBV antigens are therefore a possible target for adoptive T cell immunotherapy as their expression and, consequently, potential on-target off-tumour events, are confined to the liver compartment with no involvement of other organs. Here we summarise the research steps to develop T cell therapy that utilises viral antigen as a tumour antigen in HBV-related HCC and discuss the efficacy and the potential mechanisms of action of HBV-specific T cell receptor (TCR)-redirected T cells in phase I clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver NeoplasmsCarcinoma, HepatocellularImmunotherapy, AdoptiveHepatitis B virusReceptors, Antigen, T-CellT-LymphocytesAntigens, NeoplasmHepatitis B AntigensHepatitis B, ChronicHumansAnimalsReceptors, Chimeric AntigenTreatment Outcome

Stichwörter der Autor:innen

Adoptive T cell therapyHBV-related HCCHBV-specific TCRMRNA Transfection

Substanzen

Receptors, Antigen, T-CellAntigens, NeoplasmHepatitis B AntigensReceptors, Chimeric Antigen

Autor:innen und Institutionen

  • Programme Emerging Infectious Diseases, Duke-NUS Medical School, Singapore.
  • Programme Emerging Infectious Diseases, Duke-NUS Medical School, Singapore. Electronic address: antonio@duke-nus.edu.sg.

Förderung

  • Government of Singapore Ministry of Health

Zitieren

APA

He, S., Tan, A. T., & Bertoletti, A. (2025). HBV antigen as a tumour antigen in adoptive TCR-T cell therapy for HBV-related HCC: rationale and clinical effectiveness. Seminars in Immunology. https://doi.org/10.1016/j.smim.2025.102004

Vancouver

He S, Tan AT, Bertoletti A. HBV antigen as a tumour antigen in adoptive TCR-T cell therapy for HBV-related HCC: rationale and clinical effectiveness. Seminars in Immunology. 2025. doi:10.1016/j.smim.2025.102004

BibTeX
@article{He2025,
  author = {He, Shan and Tan, Anthony T and Bertoletti, Antonio},
  title = {HBV antigen as a tumour antigen in adoptive TCR-T cell therapy for HBV-related HCC: rationale and clinical effectiveness},
  journal = {Seminars in Immunology},
  year = {2025},
  doi = {10.1016/j.smim.2025.102004}
}
Kostenlos starten →